Abstract PS2-12-06: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
K. W. Sinkevicius, J. P. Stice, Cathy Zhang, Siyu Feng et autres
Abstract Aberrant activation of the PI3Kα pathway is one of the most frequent oncogenic events across human cancers and leads to promotion of tumor cell growth, survival, glucose metabolism, and acute resistance to numerous standard of care cancer therapies. Although PI3Kα inhibitors …
us (code pays fourni par la source)
0 citations
Clinical Cancer Research